Companies: 10,795·Total market cap: $144.5T
Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSCNASDAQHealthcare● Active
$0.25
$-0.00(-0.43%)
Market Cap$2347288
P/E Ratio—
52W High$2.75
52W Low$0.23
Cash on HandFinancialsRevenue

Ensysce Biosciences, Inc. (ENSC) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

ENSC · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$4.3M▲ +23.1% vs prior year
FY · as of Dec 31, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$4.3M
cashAndCashEquivalents
Short-Term Investments
$0
shortTermInvestments
YoY Change vs Prior Year
+23.1%
vs prior fiscal year
Latest Quarter
$745,482
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$4.3MCash on Hand
Total Debt$306.71BTotal Debt
Net Cash / Net Debt−$306.70BNet Debt Position
Cash vs Debt Ratio
Cash 0%Debt 100%

Ensysce Biosciences, Inc. carries a net debt position of $306.70B. Total debt ($306.71B) exceeds cash on hand ($4.3M). Ensysce Biosciences, Inc. cash vs debt ratio: 0% cash / 100% debt.

Net Cash = Cash & ST Investments − Total Debt$4.3M − $306.71B = −$306.70B

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
ENSC annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$4.3M+23.1%
Dec 31, 2024$3.5M+211.7%
Dec 31, 2023$1.1M-64.3%
Dec 31, 2022$3.1M-74.3%
Dec 31, 2021$12.3M+6215.1%
ENSC cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.6%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc.YOU
ENSC
$4.3M183.6%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Ensysce Biosciences, Inc. (ENSC) cash on hand as of December 31, 2025 is $4.3M, comprising $4.3M in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Ensysce Biosciences, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Ensysce Biosciences, Inc. cash reserves or cash position.

Ensysce Biosciences, Inc. annual cash on hand history shows increased +23.1% in 2025: increased +23.1% in 2025. Ensysce Biosciences, Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

Ensysce Biosciences, Inc. carries total debt of $306.71B against cash of $4.3M, resulting in a net debt position of -$306.70B. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

ENSC cash on hand · 5 questions

As of December 31, 2025, Ensysce Biosciences, Inc. (ENSC) has $4,310,354 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $4,310,354 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $745,482. Data sourced from the annual 10-K filing via FMP.

ENSC cash on handENSC cash reservesENSC cash 2025how much cash does ENSC have

▸ Source: FMP /balance-sheet-statement · US GAAP · Ensysce Biosciences, Inc. · Ensysce Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025